Cilazapril

• CAT Number: I005327
• CAS Number: 88768-40-5
• Molecular Formula: C22H31N3O5
• Molecular Weight: 417.5
• Purity: ≥95%
• Target: ACE
• Solubility: 10 mM in DMSO
• Storage: Store at -20℃
• IUPAC Name: (4S,7S)-7-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-6-oxo-1,2,3,4,7,8,9,10-octahydropyridazino[1,2-a]diazepine-4-carboxylic acid
• InChI: InChI=1S/C22H31N3O5/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28)/t17-,18-,19-/m0/s1
• InChIKey: HHHKFGXWKKUNCY-FHWLQOOXSA-N
• SMILES: CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(=O)O

Cilazapril (Cat.No:I005327) is an angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension (high blood pressure) and congestive heart failure. It works by inhibiting the activity of ACE, an enzyme responsible for the production of angiotensin II, a substance that constricts blood vessels and increases blood pressure. By blocking ACE, cilazapril helps relax blood vessels, lowers blood pressure, and improves cardiac function. It is commonly prescribed as part of a comprehensive treatment plan for cardiovascular conditions.

Reference

1:Multicriteria Optimization Methodology in Stability-Indicating Method Development of Cilazapril and Hydrochlorothiazide. Šljivic J, Protic A, Otaševic B, Golubovic J, Zecevic M, Krmar J.J Chromatogr Sci. 2017 Mar 17:1-13. doi: 10.1093/chromsci/bmx018. [Epub ahead of print] PMID: 28334985 2:Use of LC-MS/TOF, LC-MS(n), NMR and LC-NMR in characterization of stress degradation products: Application to cilazapril. Narayanam M, Sahu A, Singh S.J Pharm Biomed Anal. 2015;111:190-203. doi: 10.1016/j.jpba.2015.03.038. Epub 2015 Apr 3. PMID: 25890215 3:Stability of cilazapril in pediatric oral suspensions prepared from commercially available tablet dosage forms. Stanisz BJ, Paszun SK, Zalewska A.Acta Pol Pharm. 2014 Jul-Aug;71(4):661-6. PMID: 25272892 Free Article4:Thermal analysis study of antihypertensive drugs telmisartan and cilazapril. Saber RA, Attia AK, Salem WM.Adv Pharm Bull. 2014;4(3):283-7. doi: 10.5681/apb.2014.041. Epub 2014 Feb 7. PMID: 24754013 Free PMC Article5:Cilazapril stability in the presence of hydrochlorothiazide in model mixtures and fixed dose combination. Paszun SK, Stanisz BJ, Gradowska A.Acta Pol Pharm. 2013 Nov-Dec;70(6):1079-85. PMID: 24383331 Free Article6:Rapid and simple stability indicating HPLC method for the determination of cilazapril in pure substance and pharmaceutical formulation in comparison with classic and derivative spectrophotometric methods. Paszun SK, Stanisz B, Pawłowski W.Acta Pol Pharm. 2012 Mar-Apr;69(2):193-201. PMID: 22568033 Free Article7:Advantages of automation in plasma sample preparation prior to HPLC/MS/MS quantification: application to the determination of cilazapril and cilazaprilat in a bioequivalence study. Kolocouri F, Dotsikas Y, Apostolou C, Kousoulos C, Soumelas GS, Loukas YL.J AOAC Int. 2011 May-Jun;94(3):758-64. PMID: 21797003 8:Cilazapril-induced pleural effusion: A case report and review of the literature. Zaki SA, Nilofer AR.Ann Thorac Med. 2011 Jul;6(3):157-8. doi: 10.4103/1817-1737.82459. No abstract available. PMID: 21760854 Free PMC Article9:Effects of bisoprolol and cilazapril on the central retinal artery blood flow in patients with essential hypertension–preliminary results. Madej A, Gierek-Ciaciura S, Haberka M, Lekston-Madej J, Basiak M, Domańska O, Okopień B.Ups J Med Sci. 2010 Nov;115(4):249-52. doi: 10.3109/03009734.2010.487951. Epub 2010 Sep 22. PMID: 20858158 Free PMC Article10:Cilazapril-induced pleural effusion: A case report and review of the literature. Kupeli E, Ulubay G, Ulasli SS, Kilic D.Ann Thorac Med. 2010 Jul;5(3):171-3. doi: 10.4103/1817-1737.65043. PMID: 20835313 Free PMC Article